ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Immunotherapeutic strategies for treating opioid use disorder and overdose.Expert opinion on investigational drugs · 2023Review
- Immunotherapies for the Treatment of Drug Addiction.Vaccines · 2022Review
- Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
- A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.ImmunoTargets and therapy · 2022Review
- Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.Neuropharmacology · 2020Review
- Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer.Cancer research · 2020Article
- The discriminative stimulus effects of epibatidine in C57BL/6J mice.Behavioural pharmacology · 2020Article
- Improving immunogenicity and safety of flagellin as vaccine carrier by high-density display on virus-like particle surface.Biomaterials · 2020Article
- Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.Immunological reviews · 2020Review
- Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity.Vaccine · 2020Article
- Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?CNS drugs · 2020Review
- Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.The Journal of pharmacology and experimental therapeutics · 2018Article
- Utility of Nonhuman Primates in Substance Use Disorders Research.ILAR journal · 2017Review
- Conjugate Vaccine Immunotherapy for Substance Use Disorder.Pharmacological reviews · 2017Review
- Development of a Clinically Viable Heroin Vaccine.Journal of the American Chemical Society · 2017Article
- The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pANeuropharmacology · 2017Article
- Article
- Biologics to treat substance use disorders: Current status and new directions.Human vaccines & immunotherapeutics · 2016Review
- New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?CNS drugs · 2016Review
- Nicotinic effects of tobacco smoke constituents in nonhuman primates.Psychopharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key feature of addiction to nicotine likely resides in its ability to produce subjective effects that, in turn, may be reflected in its discriminative-stimulus properties. Vaccination against such effects of nicotine offers an intriguing therapeutic approach for smoking cessation, but a reliably effective and immunologically safe vaccine remains to be identified. Here we report on the ability of SEL-068, a nanoparticle-based vaccine that targets nicotine, to modify the discriminative-stimulus effects of nicotine in a primate species. Results indicate that squirrel monkeys vaccinated with SEL-068 failed to acquire 0.1 mg/kg nicotine discrimination but readily learned to discriminate 0.001 mg/kg of the nicotinic full agonist (+)-epibatidine ((+)-EPI). After (+)-EPI training, doses of nicotine ⩾ 0.32 mg/kg, which produced behaviorally adverse actions, still failed to substitute for the (+)-EPI training stimulus in immunized monkeys, whereas (+)-EPI and the partial agonist varenicline engendered, respectively, complete and partial substitution in all monkeys with potency comparable to their potency in non-immunized subjects. In other subjects, nicotine was trained as a discriminative-stimulus and then replaced by (+)-EPI. Subsequent vaccination with SEL-068 led to a threefold and long-lasting (>30 weeks) decrease in the potency of nicotine but not (+)-EPI or varenicline. Collectively, our results show that SEL-068 can block the development of nicotine discrimination and attenuate nicotine's effects in nicotine-experienced monkeys without altering the discriminative-stimulus properties of other nicotinic drugs. The difference in the vaccine's effects in naive and nicotine-experienced subjects provides important insight into the conditions under which immunotherapy may be effective in combating nicotine addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.